Ellen Wagner

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: The University of Texas System, Synthetic Biologics, Inc., Gigamune, Inc.. Active years: 2016-2026.

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Austin, TX (US) (2016)
Larkspur, CO (US) (2018 - 2020)
San Mateo, CA (US) (2020 - 2022)

Company Filing History:

5 out of 5,622

The University of Texas System

patents

3 out of 39

Synthetic Biologics, Inc.

where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649772 - HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLS (2026-06-09),

2. 12497711 - Engineered Cells Expressing Anti-Viral T Cell Receptors and Methods of Use Thereof (2025-12-16),

3. 11421220 - Engineered cells expressing anti-viral T cell receptors and methods of use thereof (2022-08-23),

4. 10538579 - Bispecific pertussis antibodies (2020-01-21),

5. 10526400 - Humanized pertussis antibodies and used thereof (2020-01-07),

6. 10035846 - Humanized pertussis antibodies and uses thereof (2018-07-31),

7. 9512204 - Humanized pertussis antibodies and uses thereof (2016-12-06),

Title: The Innovative Contributions of Ellen Wagner

Introduction

Ellen Wagner, an accomplished inventor based in Larkspur, Colorado, has made notable strides in the fields of biotechnology and therapeutic applications. With a total of five patents to her name, Wagner has focused her research on developing advanced solutions to combat viral infections and improve immunotherapies.

Latest Patents

Among her latest innovations is a patent for engineered cells expressing anti-viral T cell receptors. This invention provides compositions comprising recombinant mammalian cells that express T cell receptors targeted at Epstein-Barr virus (EBV) or cytomegalovirus (CMV) peptide:MHC antigens. The therapeutic methods detailed in this patent propose using these engineered cells as effective cell therapies against viral infections. Another significant patent involves bispecific pertussis antibodies that can bind to the pertussis toxin protein. This invention aims to enhance the prevention and treatment of infections caused by pertussis.

Career Highlights

Ellen Wagner has had an impressive career trajectory, holding positions in notable organizations such as the University of Texas System and Synthetic Biologics, Inc. Her work has been pivotal in advancing the understanding and treatment of viral diseases.

Collaborations

Throughout her career, Wagner has collaborated with talented individuals, including Jennifer A. Maynard and Annalee Nguyen. These partnerships have fostered a productive environment for innovation and have contributed to the progress of her research endeavors.

Conclusion

Ellen Wagner is a remarkable inventor whose contributions to biotechnology and immunotherapy continue to make a significant impact. With her innovative patents and collaborative spirit, she is poised to lead future advancements in the field of viral infection treatment.